Want to see HK:1228 full AI Analyst Report?
CANbridge Pharmaceuticals Inc. (1228) AI Stock Analysis
Top Page
CANbridge Pharmaceuticals Inc.
(HKEX:1228)
The overall score reflects weak but improving financial fundamentals, with negative equity, continued operating losses, and ongoing cash burn as the main constraints, partially offset by a constructive technical setup showing price strength above key short- and medium-term averages and positive momentum indicators; valuation remains modest due to negative earnings and no dividend, leaving upside reliant on successful execution rather than current valuation metrics.
CANbridge Pharmaceuticals Inc. (1228) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 751.96M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.44M
- Price to Earnings (P/E)
- -9.5
- Beta (1Y)
- 0.57
- Revenue Growth
- -8.00%
- EPS Growth
- 51.26%
- Country
- Hong Kong
- Employees
- 39
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model
Company Description
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme r...
How the Company Makes Money
CANbridge generally makes money through the development and commercialization of rare-disease drug assets in its target geographies. Key revenue streams typically include: (1) Product sales: revenue from selling approved therapies through specialty d...
CANbridge Pharmaceuticals Inc. Financial Statement Overview
Summary
Financials show improving gross margins and reduced cash burn, but revenue has declined, equity is deeply negative, and EBIT and operating cash flow remain consistently negative, indicating fragile and high-risk profitability.
Income Statement
45NeutralBalance Sheet
28NegativeCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 55.67M | 49.98M | 85.10M | 102.87M | 78.97M | 31.16M |
| Gross Profit | 39.79M | 36.55M | 54.30M | 64.16M | 48.89M | 18.78M |
| EBITDA | -87.79M | -80.55M | -313.26M | -341.43M | -454.63M | -1.06B |
| Net Income | -81.51M | 14.82M | -442.62M | -378.84M | -483.48M | -1.08B |
Balance Sheet | ||||||
| Total Assets | 192.38M | 165.46M | 116.81M | 395.36M | 702.04M | 892.52M |
| Cash, Cash Equivalents and Short-Term Investments | 88.10M | 66.65M | 10.50M | 137.49M | 451.16M | 745.82M |
| Total Debt | 28.81M | 16.09M | 135.78M | 141.93M | 155.28M | 52.10M |
| Total Liabilities | 388.31M | 507.36M | 591.30M | 435.15M | 393.49M | 199.13M |
| Stockholders Equity | -195.93M | -341.90M | -474.49M | -39.79M | 308.56M | 693.39M |
Cash Flow | ||||||
| Free Cash Flow | -112.02M | -38.22M | -122.50M | -319.09M | -315.76M | -592.40M |
| Operating Cash Flow | -111.98M | -38.21M | -122.39M | -278.23M | -280.98M | -587.07M |
| Investing Cash Flow | 176.00K | 1.23M | 13.93M | -26.86M | -34.79M | 126.09M |
| Financing Cash Flow | 93.14M | 92.47M | -18.57M | -28.02M | -20.70M | 854.31M |
CANbridge Pharmaceuticals Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1228, the sentiment is Negative. The current price of 1.77 is below the 20-day moving average (MA) of 1.89, below the 50-day MA of 1.92, and below the 200-day MA of 2.23, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.01 is Neutral, neither overbought nor oversold. The STOCH value of 17.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1228.
CANbridge Pharmaceuticals Inc. Peers Comparison
Overall Rating
HK:269664.6Neutral
HK:996652Neutral- HK:122849Neutral
HK:116748Neutral
HK:187741.25Neutral
HK:217139Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1228 | 49Neutral | HKD 1.06B | -9.52 | 30.32% | ― | -8.00% | 51.26% |
| HK:1167 | 48Neutral | HKD 3.62B | 6.00 | 47.76% | ― | 286.20% | ― |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
| HK:2171 | 39Underperform | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1228 | CANbridge Pharmaceuticals Inc. | 1.77 | -0.21 | -10.61% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:1167 | Jacobio Pharmaceuticals Group Co., Ltd. | 4.60 | -2.66 | -36.64% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
CANbridge Pharmaceuticals Inc. Corporate Events
CANbridge boosts rare disease footprint after HK$200 million WuXi stake
CANbridge Pharmaceuticals reported interim results marked by a strategic HK$200 million investment from WuXi Biologics HealthCare Venture, which acquired a 16.27% stake and became the company’s second-largest shareholder. The proceeds are earma...
CANbridge Wins Taiwan NHIA Reimbursement for Rare Disease Drug Livmarli
CANbridge Pharmaceuticals Inc. announced that its rare disease drug Livmarli has received reimbursement approval from Taiwan’s National Health Insurance Administration. The coverage, effective September 1, 2026, applies to patients with Alagill...
CANbridge sets August board meeting to approve 2026 interim results
CANbridge Pharmaceuticals Inc. has scheduled a board meeting for August 28, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The meeting will also authorize publication of these interim figures, a routi...
CANbridge Pharmaceuticals Refreshes Board and Committee Leadership With New Independent Director
CANbridge Pharmaceuticals Inc., a Hong Kong-listed biopharmaceutical company, has announced changes to its board and committee leadership. The firm relies on independent non-executive directors to oversee remuneration and audit functions, reflecting...
CANbridge Pharmaceuticals Details Board and Committee Structure
CANbridge Pharmaceuticals has outlined the composition of its board of directors, naming Chairman and Chief Executive Officer Dr. James Qun Xue as the sole executive director alongside two non-executive directors and four independent non-executive di...
CANbridge Shareholders Unanimously Approve WuXi Biologics Service Agreement
CANbridge Pharmaceuticals shareholders have approved, by poll, an ordinary resolution endorsing the WuXi Biologics Service Procurement Framework Agreement at an extraordinary general meeting held on August 3, 2026. Under the approved framework, direc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026